Effects of erythromycin on hepatic drug-metabolizing enzymes in humans

doi:10.1016/0006-2952(83)90626-3

Biochemical Pharmacology

Volume 32, Issue 6, 15 March 1983, Pages 1063-1068

https://doi.org/10.1016/0006-2952(83)90626-3 Get rights and content

Abstract

In rats, erythromycin has been shown to induce microsomal enzymes and to promote its own transformation into a metabolite which forms an inactive complex with reduced cytochrome P-450. To determine whether similar effects also occur in humans, we studied hepatic microsomal enzymes from six untreated patients and six patients treated with erythromycin propionate, 2 g per os daily for 7 days In the treated patients, NADPH-cytochrome c reductase activity was increased; the total cytochrome P-450 concn was also increased but part of the total cytochrome P-450 was complexed by an erythromycin metabolite. The concn of uncomplexed (active) cytochrome P-450 was not significantly modified and the activity of hexobarbital hydroxylase remained unchanged. We also measured the clearance of antipyrine in six other patients; this clearance was not significantly decreased when measured again on the seventh day of the erythromycin propionate treatment. We conclude that the administration of erythromycin propionate induces microsomal enzymes and results in the formation of an inactive cytochrome P-450-metabolite complex in humans. However, the concn of uncomplexed (active) cytochrome P-450 and tests for in vitro and in vivo drug metabolism were not significantly modified.

References (29)

C. Dravet et al.
Lancet
(1977)
M. Weinberger et al.
J. Allergy clin. Immun.
(1977)
B.J. Kimelblatt et al.
J. Allergy clin. Immun.
(1980)
D. Pessayre et al.
Biochem. Pharmac.
(1981)
D. Pessayre et al.
Biochem. Pharmac.
(1981)
D. Pessayre et al.
Biochem. Pharmac.
(1982)
T. Omura et al.
J. biol. Chem.
(1964)
D. Pessayre et al.
Biochem. Pharmac.
(1976)
O.H. Lowry et al.
J. biol. Chem.
(1951)
B.B. Brodie et al.
J. biol. Chem.
(1949)

M.R. Franklin

Pharmac. Ther.

(1977)

S.J. Szefler et al.

J. Allergy clin. Immun.

(1980)

A.C. Hayton

N.Z. med. J.

(1969)

J.P. Miguet et al.

Ann. intern. Med.

(1980)

Cited by (115)

Pro-inflammatory cytokines enhance dilatation of bile canaliculi caused by cholestatic antibiotics
2019, Toxicology in Vitro
Citation Excerpt :
Accordingly, this drug has to be used at high concentrations to cause cytotoxic damage in HepaRG cells (Burban et al., 2018) and contrary to TVX, it was not more cytotoxic with TNF-α than with other cytokines, supporting previous observations (Cosgrove et al., 2009). As other macrolide ATBs, ERY has been shown to form P450-Fe2+-metabolite complexes after CYP3A4-mediated activation (Larrey et al., 1983; Yamazaki et al., 1996). In the present study, ERY was found to be less cytotoxic when co-added with the cytokine mixture while individual cytokines were ineffective.
Many drugs can induce liver injury, characterized by hepatocellular, cholestatic or mixed hepatocellular-cholestatic lesions. While an inflammatory stress is known to aggravate hepatocellular injury caused by some drugs much less evidence exists for cholestatic features. In this study, the influence of pro-inflammatory cytokines (IL-6, IL-1β and TNF-α), either individually or combined, on cytotoxic and cholestatic properties of antibiotics was evaluated using differentiated HepaRG cells. Six antibiotics of various chemical structures and known to cause cholestasis and/or hepatocellular injury in clinic were investigated. Caspase-3 activity was increased with all these tested hepatotoxic drugs and except with erythromycin, was further augmented in presence of cytokines mainly when these were co-added as a mixture. TNF-α and IL-1β aggravated cytotoxicity of TVX more than IL-6. Bile canaliculi (BC) dilatation induced by cholestatic drugs was increased by co-treatment with IL-6 and IL-1β but not with TNF-α. Reduced accumulation of carboxy-dichlorofluorescein, a substrate of the multi-drug resistance-associated protein 2, in antibiotic–induced dilatated BC, was further extended in presence of individual or mixed cytokines. In conclusion, our data demonstrate that pro-inflammatory cytokines either individually or in mixture, can modulate cholestatic and/or cytotoxic responses to antibiotics and that the extent of these effects is dependent on the cytokine and the cholestatic antibiotic.
Assessment of toxic effects of the antibiotic erythromycin on the marine fish gilthead seabream (Sparus aurata L.) by a multi-biomarker approach
2019, Chemosphere
Citation Excerpt :
Dehydration and composite approaches with demethylation/descladinose, as additional routes of metabolism (more details in Liu et al., 2014; Singh et al., 2014a). Additionally, some investigations have demonstrated that ERY can strongly inhibit CYPs by forming inactive complexes with CYP3A4 (e.g. in mammals) through their nitrosoalkane metabolites (Larrey et al., 1983; Rai et al., 2014; Fohner et al., 2016). Furthermore, during ERY metabolism, nitrosoalkanes derivatives are formed due to oxidative metabolism, and these can form stable and inactive complexes with the iron of cytochrome P450 isoenzymes (Pessayre et al., 1985; Periti et al., 1992; Singh et al., 2014a, 2014b).
Erythromycin (ERY) is one of the most common antibiotics used in human and veterinary practices, leading to ubiquitous environmental distribution and possible toxicity to non-target organisms. The purpose of this study was to determine sub-lethal effects of ERY towards the marine fish Sparus aurata (gilthead seabream). S. aurata were acutely (0.3–323 μg/L, 96 h) and chronically (0.7–8.8 μg/L, 28 d) exposed to ERY. Detoxification [7-ethoxyresorufin O-deethylase (EROD), glutathione S-transferases (GSTs), uridine-diphosphate-glucuronosyltransferase (UGT)], oxidative stress [catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GRed)], lipid peroxidation [thiobarbituric acid reactive substances - (TBARS)], genotoxicity [genetic damage index (GDI) and erythrocytic nuclear abnormalities (ENAs)], neurotransmission [acetylcholinesterase (AChE)] and energy metabolism [lactate dehydrogenase (LDH)] biomarkers were evaluated. Results showed that ERY did not promote significant effects in detoxification biomarkers, but induced slight pro-oxidative effects (decrease of GPx activity in the liver after acute exposure and an increase in gills after chronic exposure; and an increase of hepatic GRed activity following chronic exposure). There was a significant decrease in TBARS after chronic exposure, which contradicts a full scenario of oxidative stress. In terms of genotoxicity, both ERY exposures caused only a significant increase of GDI. Neurotransmission and energy metabolism were not also affected by ERY. Although few toxic effects of ERY have been previously documented (involving different metabolic pathways, as tested in this work), these were mainly observed for freshwater species. These findings suggest low vulnerability of S. aurata to ERY at levels close to the ones found in the wild.
Monitoring drug-protein interaction
2006, Clinica Chimica Acta
A variety of therapeutic drugs can undergo biotransformation via Phase I and Phase II enzymes to reactive metabolites that have intrinsic chemical reactivity toward proteins and cause potential organ toxicity. A drug–protein adduct is a protein complex that forms when electrophilic drugs or their reactive metabolite(s) covalently bind to a protein molecule. Formation of such drug–protein adducts eliciting cellular damages and immune responses has been a major hypothesis for the mechanism of toxicity caused by numerous drugs. The monitoring of protein–drug adducts is important in the kinetic and mechanistic studies of drug–protein adducts and establishment of dose–toxicity relationships. The determination of drug–protein adducts can also provide supportive evidence for diagnosis of drug-induced diseases associated with protein–drug adduct formation in patients. The plasma is the most commonly used matrix for monitoring drug–protein adducts due to its convenience and safety. Measurement of circulating antibodies against drug–protein adducts may be used as a useful surrogate marker in the monitoring of drug–protein adducts. The determination of plasma protein adducts and/or relevant antibodies following administration of several drugs including acetaminophen, dapsone, diclofenac and halothane has been conducted in clinical settings for characterizing drug toxicity associated with drug–protein adduct formation. The monitoring of drug–protein adducts often involves multi-step laboratory procedure including sample collection and preliminary preparation, separation to isolate or extract the target compound from a mixture, identification and determination. However, the monitoring of drug–protein adducts is often difficult because of short half-lives of the protein adducts, sampling problem and lack of sensitive analytical techniques for the protein adducts. Currently, chromatographic (e.g. high performance liquid chromatography) and immunological methods (e.g. enzyme-linked immunosorbent assay) are two major techniques used to determine protein adducts of drugs in patients. The present review highlights the importance for clinical monitoring of drug–protein adducts, with an emphasis on methodology and with a further discussion of the application of these techniques to individual drugs and their target proteins.
Irreversible Enzyme Inhibition Kinetics and Drug–Drug Interactions
2021, Methods in Molecular Biology
Mechanism-Based Inhibition of Human Cytochromes P450: In Vitro Kinetics and In Vitro-ln Vivo Correlations
2019, Drug-Drug Interactions, Second Edition
Toxicity of erythromycin to Oncorhynchus mykiss at different biochemical levels: detoxification metabolism, energetic balance, and neurological impairment
2019, Environmental Science and Pollution Research

View all citing articles on Scopus

View full text

Effects of erythromycin on hepatic drug-metabolizing enzymes in humans

Abstract

Lancet

J. Allergy clin. Immun.

J. Allergy clin. Immun.

Biochem. Pharmac.

Biochem. Pharmac.

Biochem. Pharmac.

J. biol. Chem.

Biochem. Pharmac.

J. biol. Chem.

J. biol. Chem.

Pharmac. Ther.

J. Allergy clin. Immun.

N.Z. med. J.

Ann. intern. Med.